Company intelligence / Profile preview

āshi bio

South San Francisco, California, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Ashi Bio is a preclinical-stage biotechnology company focused on developing novel small molecule therapeutics for metabolic diseases, including obesity and type 2 diabetes. The company utilizes a proprietary discovery platform that integrates human genetics and functional genomics to identify and validate high-impact targets that regulate energy homeostasis. By focusing on the underlying biological drivers of metabolic dysfunction, Ashi Bio aims to create next-generation treatments that offer improved efficacy and safety profiles compared to current standards of care. The company is backed by prominent life science investors and is headquartered in the San Francisco Bay Area.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on āshi bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on āshi bio.

Explore the full profile